Join
Live feed
·
PRReleasevia Quantisnow
Nektar Therapeutics logo

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
NKTR· Nektar Therapeutics
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NKTR (Nektar Therapeutics) and more on Quantisnow.